Skip to content

Today is world diabetes day (Merck ends MK-0431E)

November 14, 2012

As WHO and other organisations are celebrating World Diabetes Day (WDD) it is always sad to read that a new potential drug is stopped.

This time Merck & co. stopped the clinical trial MK-0431E studying the co-administration of Sitagliptin and Atorvastatin in inadequately controlled Type 2 Diabetes Mellitus. Merck cites “business reasons” without further explanations.

Sitagliptin is sold under the trade name Januvia. It is an oral antihyperglycemic and one of the (if not the) best selling product of Merck with US$975 million revenue in the third quarter of 2012. On the other hand Atorvastatin is a statin lowering blood cholesterol. It was a blockbuster for Pfizer (sold under the trade name of Lipitor) until its patent expired.

Combining these two molecules made biological sense in order to reduce the number of medications that diabetic patients take. Of course combining two blockbusters (including one which patent expired) is a nice attempt to maintain drugs and positions on market.

From → Health, Lab life

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 141 other followers

%d bloggers like this: